Progression-free survival reached 77% at 20 months in the target HLA-selected population of Scancell’s Phase 2 SCOPE trial when iSCIB1+ was added to ipilimumab plus nivolumab. That compares with 43% PFS at 20 months reported for ipilimumab plus nivolumab alone in the historical CheckMate 067 study, implying a 30+ percentage point advantage on a cross-trial basis. Additional PFS reads and early overall survival data are slated for the first half of 2027.
The core development is FDA Fast Track designation for iSCIB1+ in advanced melanoma, positioning Scancell to increase cadence with the agency ahead of a planned registrational Phase 3 launch in the second half of 2026. SCOPE is a multicenter, open-label Phase 2 where patients on standard checkpoint backbones (nivolumab plus ipilimumab or pembrolizumab) also receive SCIB1 or the next-generation iSCIB1+. The company’s target Phase 3 population reflects HLA alleles present in roughly 80% of patients in SCOPE’s third cohort, with dosing delivered via a needle-free injector.
Strategically, this is an add-on play designed to extract more durable disease control from established checkpoint regimens without introducing a new immunotherapy mechanism that escalates immune-related toxicity management. Fast Track offers procedural advantages—more frequent interactions, rolling submissions, and potential accelerated pathways—but the core tension remains evidentiary: the headline PFS signal is anchored in cross-trial comparison to an older control and in a selected HLA subset. The registrational program will need to translate that advantage into a prospectively powered, randomized setting against a contemporary control, and clarify where the vaccine adds the most value—on CTLA-4/PD-1 doublet backbones or on PD-1 monotherapy where room for improvement may be larger but comparators have evolved.
For sites and CROs, the operational footprint is manageable but not trivial. HLA typing becomes a gating step, adding pre-screening logistics and lab turnaround to front-end workflows, even if coverage at approximately four-fifths of patients reduces screen-fail risk. Coordinating vaccine administrations alongside checkpoint infusion schedules and training staff on a needle-free injector will require protocol discipline but should be feasible within standard oncology clinic operations. If immune-related adverse events remain aligned with backbone expectations, monitoring intensity may not materially increase, though regulators will scrutinize any additive safety signal. For sponsors across melanoma, the move underscores ongoing pressure to differentiate beyond PD-1/CTLA-4 via either LAG-3–based regimens or tumor-specific vaccination strategies; payers will ultimately expect robust, randomized PFS and emerging OS to justify layering cost onto entrenched standards.
The next inflection is the Phase 3 design. Key watch points include the choice of control (ipilimumab plus nivolumab versus other modern backbones), the primary endpoint and statistical hierarchy, and how HLA selection is operationalized across geographies. Event-driven timelines will hinge on the assumed control hazard rates in today’s practice environment, not historical trials, and enrollment could be competitive in a crowded melanoma landscape. Manufacturing scale-up for a DNA-based vaccine and global distribution of injection devices will need to be de-risked before late-stage acceleration. If the registrational trial can reproduce the magnitude and durability of the PFS signal with acceptable safety, the Fast Track pathway could enable an efficient review. Until then, the central question is whether the HLA-directed vaccine can consistently deliver incremental benefit across contemporary backbones and real-world patient heterogeneity without adding operational friction that slows adoption.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
